Salesforce.com (CRM) Rises But Trails Market: What Investors Should Know

Salesforce (CRM) has recently underperformed, declining 8.17% over the past month, trailing both the broader market and its sector. However, the company's upcoming earnings release on September 3, 2025, is anticipated to show robust growth, with consensus estimates projecting an 8.2% increase in EPS to $2.77 and an 8.66% rise in revenue to $10.13 billion. Despite stagnant analyst EPS estimates, CRM currently trades at a Forward P/E of 21.76 and a PEG ratio of 1.69, both representing a discount to its industry averages, within a Computer - Software industry that ranks in the top 26%.

Analysis

Salesforce.com (CRM) presents a conflicting picture, marked by significant recent share price underperformance juxtaposed with strong forward-looking growth expectations. Over the past month, the stock has declined 8.17%, substantially lagging both its sector's 0.05% loss and the S&P 500's 1.1% gain. Despite this weak momentum, consensus estimates for its upcoming earnings on September 3, 2025, are robust, projecting an 8.2% year-over-year increase in EPS to $2.77 and an 8.66% rise in revenue to $10.13 billion. Full-year forecasts are similarly positive, with expected earnings and revenue growth of 10.78% and 8.58%, respectively. However, this optimism is tempered by the fact that analyst EPS estimates have remained stagnant over the last month, a factor contributing to its neutral Zacks Rank of #3 (Hold). From a valuation standpoint, CRM appears attractive relative to its peers, trading at a Forward P/E of 21.76 and a PEG ratio of 1.69, both of which represent a discount to the industry averages of 24.96 and 2.0, respectively. This valuation is situated within a favorably ranked Computer - Software industry, which sits in the top 26% of all industries tracked by Zacks.

Key Decisions for Investors

• Investors should weigh the stock's recent technical weakness, evidenced by an 8.17% monthly decline, against its fundamental strengths, including projected double-digit full-year EPS growth and a valuation discount to its industry.
• The upcoming September 3rd earnings report is a critical catalyst; a beat on the consensus estimates for EPS ($2.77) and revenue ($10.13 billion) could reverse the negative sentiment, while a miss could exacerbate the underperformance.
• Given the stagnant analyst estimates and neutral 'Hold' rating, a cautious approach is warranted, but the discounted Forward P/E and PEG ratios may offer an attractive entry point for investors confident that the company will deliver on its growth promises.